# A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct07719361/  
OnCo record `nct07719361` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of FX-111 run by Flare Therapeutics Inc., now recruiting.

## Summary

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer is a phase 1 interventional study registered as NCT07719361 by Flare Therapeutics Inc., with 60 participants planned, started 2026-07-01, primary completion expected 2028-02-15. Conditions recorded: Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, mCRPC or Advanced/Metastatic Solid Tumors, mCRPC, Metastatic Castration Resistant Prostate Cancer, Neoplasms Prostate, Neoplasms of Prostate. Interventions recorded: FX-111.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07719361
- Phase: 1
- Setting: A Phase 1, First-in-Human, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FX-111 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Flare Therapeutics Inc.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07719361: https://clinicaltrials.gov/study/NCT07719361

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [FX-111](https://onco.cc/drugs/fx-111/)
- companies: [Flare Therapeutics](https://onco.cc/companies/flare-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07719361.json